UY37027A - PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO de Anti-TL1A/Anti-TNF-a Y SUS USOS - Google Patents

PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO de Anti-TL1A/Anti-TNF-a Y SUS USOS

Info

Publication number
UY37027A
UY37027A UY0001037027A UY37027A UY37027A UY 37027 A UY37027 A UY 37027A UY 0001037027 A UY0001037027 A UY 0001037027A UY 37027 A UY37027 A UY 37027A UY 37027 A UY37027 A UY 37027A
Authority
UY
Uruguay
Prior art keywords
tl1a
tnf
proteins
bispective
union
Prior art date
Application number
UY0001037027A
Other languages
English (en)
Inventor
Edward J Belouski
Hailing Hsu
Kenneth W Walker
Michelle Hortter
Gunasekaran Kannan
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2016/052006 external-priority patent/WO2017049004A1/en
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of UY37027A publication Critical patent/UY37027A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1058—Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Ecology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención hace referencia a proteínas de unión al antígeno que se unen a TL1A, inclusive proteínas de unión al antígeno biespecífico (p. ej., anticuerpos) a TL1A y TNF-a. Dichos anticuerpos biespecíficos pueden estar en un formato de inmunoglobulina tetramérica convencional, en el cual un par de cadena pesada-cadena ligera del anticuerpo se dirige al TL1A y el otro a TNF-a.
UY0001037027A 2015-12-16 2016-12-15 PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO de Anti-TL1A/Anti-TNF-a Y SUS USOS UY37027A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562268432P 2015-12-16 2015-12-16
US201662333063P 2016-05-06 2016-05-06
PCT/US2016/052006 WO2017049004A1 (en) 2015-09-15 2016-09-15 Tetravalent bispecific and tetraspecific antigen binding proteins and uses thereof

Publications (1)

Publication Number Publication Date
UY37027A true UY37027A (es) 2017-06-30

Family

ID=59057540

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037027A UY37027A (es) 2015-12-16 2016-12-15 PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO de Anti-TL1A/Anti-TNF-a Y SUS USOS

Country Status (24)

Country Link
US (2) US11104745B2 (es)
EP (1) EP3390444A1 (es)
JP (1) JP7263007B2 (es)
KR (1) KR20180099723A (es)
CN (1) CN109311971B (es)
AU (2) AU2016370659B2 (es)
BR (1) BR112018012096A2 (es)
CA (1) CA3008267A1 (es)
CL (3) CL2018001596A1 (es)
CO (1) CO2018007355A2 (es)
CR (1) CR20180365A (es)
EA (1) EA201891322A1 (es)
IL (2) IL314885A (es)
JO (1) JO3816B1 (es)
MA (1) MA44060A (es)
MX (1) MX2018007424A (es)
PH (1) PH12018501284A1 (es)
SG (2) SG11201804857WA (es)
TN (1) TN2019000275A1 (es)
TW (1) TWI799368B (es)
UA (1) UA124305C2 (es)
UY (1) UY37027A (es)
WO (1) WO2017106383A1 (es)
ZA (1) ZA201904491B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110229471A1 (en) 2008-11-26 2011-09-22 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
EP3495389A1 (en) 2011-09-30 2019-06-12 Teva Pharmaceuticals Australia Pty Ltd Antibodies against tl1a and uses thereof
UY35148A (es) * 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
AU2014241162A1 (en) 2013-03-27 2015-10-22 Cedars-Sinai Medical Center Mitigation and reversal of fibrosis and inflammation by inhibition of TL1A function and related signaling pathways
US10316083B2 (en) 2013-07-19 2019-06-11 Cedars-Sinai Medical Center Signature of TL1A (TNFSF15) signaling pathway
TWI703158B (zh) 2015-09-18 2020-09-01 美商希佛隆公司 特異性結合tl1a之抗體
GB201522394D0 (en) 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibodies
CN109462996A (zh) 2016-03-17 2019-03-12 西达-赛奈医疗中心 通过rnaset2诊断炎性肠病的方法
MY191324A (en) 2016-10-26 2022-06-15 Cedars Sinai Medical Center Neutralizing anti-tl1a monoclonal antibodies
US20220002425A1 (en) * 2017-06-25 2022-01-06 Systimmune, Inc. Guidance and navigation control proteins and method of making and using thereof
EP4424707A2 (en) * 2017-09-19 2024-09-04 Tillotts Pharma AG Antibody variants
EP3735270A1 (en) 2018-01-05 2020-11-11 Modernatx, Inc. Polynucleotides encoding anti-chikungunya virus antibodies
MA52366A (fr) 2018-04-25 2021-03-03 Prometheus Biosciences Inc Anticorps anti-tl1a optimisés
CN111909268B (zh) * 2019-05-07 2022-04-19 北京天成新脉生物技术有限公司 低免疫原性低ADCC/CDC功能抗TNF-α人源化单克隆抗体TCX060及其应用
JP2022533956A (ja) * 2019-05-14 2022-07-27 プロメテウス バイオサイエンシーズ，インク． Ｔｌ１ａ患者を選択する方法、システム、およびデバイス
BR112022000416A2 (pt) * 2019-07-11 2022-03-03 Wuhan Yzy Biopharma Co Ltd Anticorpo biespecífico, composição farmacêutica, conjugado, polinucleotídeo, célula e usos do anticorpo biespecífico
MX2022000726A (es) 2019-07-19 2022-02-10 Oncoresponse Inc Anticuerpos inmunomoduladores y metodos de uso de los mismos.
AU2020371725A1 (en) 2019-10-24 2022-05-26 Cedars-Sinai Medical Center Humanized antibodies to TNF-like ligand 1A (TL1A) and uses thereof
CN113121696A (zh) * 2019-12-31 2021-07-16 周易 Fab改造诱导形成的双特异性抗体及其制备方法和用途
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
JP2023530046A (ja) * 2020-04-02 2023-07-13 ラ ホヤ インスティテュート フォー イムノロジー Ｔｎｆファミリーのメンバーの二重標的化のための方法および組合せ
MX2022014420A (es) * 2020-05-20 2023-03-21 Univ Columbia Potentes anticuerpos neutralizantes contra el sars-cov-2, generacion y usos de los mismos.
JP2023534923A (ja) 2020-07-06 2023-08-15 フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー ＳＡＲＳ－ＣｏＶ－２を標的にする抗原結合分子
TW202216760A (zh) 2020-07-23 2022-05-01 愛爾蘭商歐薩爾普羅席納有限公司 抗類澱粉β (ABETA)抗體
AU2021329374A1 (en) * 2020-08-20 2023-03-09 Amgen Inc. Antigen binding proteins with non-canonical disulfide in FAB region
IL300720A (en) 2020-08-26 2023-04-01 Flagship Pioneering Innovations Vi Llc Antigen binding molecules targeting Sars-cov-2

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603044A (en) 1983-01-06 1986-07-29 Technology Unlimited, Inc. Hepatocyte Directed Vesicle delivery system
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
JP3202999B2 (ja) 1991-01-31 2001-08-27 協和醗酵工業株式会社 肝移行性リポソーム製剤
US5830877A (en) 1993-08-26 1998-11-03 The Regents Of The University Of California Method, compositions and devices for administration of naked polynucleotides which encode antigens and immunostimulatory
US7820798B2 (en) 1994-11-07 2010-10-26 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
AU728657B2 (en) 1996-03-18 2001-01-18 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
CA2273194C (en) 1996-12-03 2011-02-01 Abgenix, Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
CA2323929C (en) 1998-04-03 2004-03-09 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
CN101066997B (zh) 1999-03-25 2013-03-27 艾博特股份有限两合公司 结合人il-12的人抗体及其生产方法
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
AU783682B2 (en) 1999-08-04 2005-11-24 Amgen, Inc. Fhm, a novel member of the TNF ligand supergene family
ES2347239T3 (es) 2002-12-02 2010-10-27 Amgen Fremont Inc. Anticuerpos dirigidos al factor de necrosis tumoral y usos de los mismos.
US20080233119A2 (en) 2003-08-20 2008-09-25 University Of Miami Compositions and methods for treating inflammatory lung disease
EP1870459B1 (en) 2005-03-31 2016-06-29 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US20110217310A1 (en) 2007-01-10 2011-09-08 Siegel Richard M Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology
EA020886B1 (ru) 2007-11-13 2015-02-27 ТЕВА БИОФАРМАСЬЮТИКАЛЗ ЮЭсЭй, ИНК. Гуманизированные антитела против tl1a
HUE028536T2 (en) 2008-01-07 2016-12-28 Amgen Inc Method for producing antibody to FC heterodimer molecules using electrostatic control effects
ES2828627T3 (es) 2008-04-25 2021-05-27 Kyowa Kirin Co Ltd Anticuerpo multivalente estable
JP5612663B2 (ja) 2009-04-07 2014-10-22 ロシュ グリクアート アクチェンゲゼルシャフト 二重特異性抗ＥｒｂＢ−１／抗ｃ−Ｍｅｔ抗体
US8703132B2 (en) 2009-06-18 2014-04-22 Hoffmann-La Roche, Inc. Bispecific, tetravalent antigen binding proteins
JO3375B1 (ar) 2010-11-08 2019-03-13 Regeneron Pharma أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a)
WO2012088302A2 (en) 2010-12-22 2012-06-28 Abbott Laboratories Half immunoglobulin binding proteins and uses thereof
EP2655415A4 (en) 2010-12-22 2016-03-09 Abbvie Inc THREE VARIABLE DOMAIN LINK PROTEINS AND USES THEREOF
KR20140104344A (ko) 2011-05-20 2014-08-28 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 시크리터리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비시스 Ｔ 세포 매개성 질병의 병증을 개선하기 위한 ｔｌ１ａ-ｄｒ３의 상호작용의 차단 및 그것의 항체
MX2014003313A (es) 2011-09-23 2014-07-09 Amgen Res Munich Gmbh Moleculas de union biespecificas para 5t4 y cd3.
EP3495389A1 (en) 2011-09-30 2019-06-12 Teva Pharmaceuticals Australia Pty Ltd Antibodies against tl1a and uses thereof
SI2852615T1 (sl) 2012-05-22 2019-02-28 Bristol-Myers Squibb Company IL-17A/F IL-23 bispecifična protitelesa in njihova uporaba
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
BR112015012385A2 (pt) 2012-11-28 2019-08-27 Zymeworks Inc constructo de polipeptídeo de ligação de antígeno isolado, polinucleotídeo isolado ou conjunto de polinucleotídeos isolados, vetor ou conjunto de vetores, célula isolada, composição farmacêutica, uso do constructo, método para tratar um sujeito tendo uma doença ou distúrbio ou câncer ou doença vascular, método para inibir, reduzir ou bloquear um sinal dentro de uma célula, método para obter o constructo, método para preparar o constructo, meio de armazenamento legível por computador, método implementado por computador e método para produzir um constructo de polipeptídeo de ligação de antígeno bi-específico
CN105102067B (zh) 2013-01-02 2020-03-03 艾科诺斯科技股份有限公司 结合tl1a的抗体及其用途
TW201444867A (zh) 2013-03-08 2014-12-01 Lilly Co Eli 抗ｔｎｆ－抗ｉｌ－１７雙特異性抗體
JOP20140087B1 (ar) 2013-03-13 2021-08-17 Amgen Inc بروتينات مخصصة ل baff و b7rp1 وإستخداماتها
US9580486B2 (en) 2013-03-14 2017-02-28 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
AU2014227638A1 (en) 2013-03-15 2015-09-17 Merck Patent Gmbh Tetravalent bispecific antibodies
BR112015023752B1 (pt) 2013-03-15 2023-11-14 Zyngenia, Inc. Domínio de reconhecimento modular (mrd), complexo compreendendo mrd e cetuximabe, usos do complexo para inibir a angiogênese e tratar câncer e composição farmacêutica compreendendo o dito complexo
UA118028C2 (uk) 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
CA3056647A1 (en) 2013-11-13 2015-05-21 Robert ARCH Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof
US20160052006A1 (en) 2013-11-22 2016-02-25 Sheila S. Pirtle Spray Bottle

Also Published As

Publication number Publication date
AU2024200534A1 (en) 2024-04-11
CL2023002597A1 (es) 2024-03-15
TW201731871A (zh) 2017-09-16
IL314885A (en) 2024-10-01
JP2019502692A (ja) 2019-01-31
MX2018007424A (es) 2018-09-21
CO2018007355A2 (es) 2018-07-19
SG11201804857WA (en) 2018-07-30
TN2019000275A1 (en) 2021-05-07
EP3390444A1 (en) 2018-10-24
SG10201912002YA (en) 2020-02-27
EA201891322A1 (ru) 2019-01-31
UA124305C2 (uk) 2021-08-25
AU2016370659A1 (en) 2018-06-28
CA3008267A1 (en) 2017-06-22
AU2016370659B2 (en) 2024-02-15
IL259847A (en) 2018-07-31
TWI799368B (zh) 2023-04-21
WO2017106383A1 (en) 2017-06-22
JO3816B1 (ar) 2021-01-31
US20190119407A1 (en) 2019-04-25
PH12018501284A1 (en) 2019-01-28
CR20180365A (es) 2018-09-28
US11104745B2 (en) 2021-08-31
KR20180099723A (ko) 2018-09-05
JP7263007B2 (ja) 2023-04-24
CN109311971A (zh) 2019-02-05
CL2021001179A1 (es) 2021-11-19
ZA201904491B (en) 2020-03-25
US20220213226A1 (en) 2022-07-07
WO2017106383A4 (en) 2017-09-08
BR112018012096A2 (pt) 2018-11-27
CL2018001596A1 (es) 2018-09-28
MA44060A (fr) 2018-10-24
CN109311971B (zh) 2024-09-24

Similar Documents

Publication Publication Date Title
UY37027A (es) PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO de Anti-TL1A/Anti-TNF-a Y SUS USOS
ECSP17081420A (es) Anticuerpos heterodiméricos que se unen a cd3 y a antígenos tumorales
CL2018000502A1 (es) Anticuerpos biespecíficos para pd1 y tim3 útiles como inmunomoduladores o en el tratamiento del cáncer.
DOP2018000259A (es) Proteínas de unión biespecíficas que se unen a una proteína inmunomoduladora y a un antígeno tumoral
CR20170383A (es) Anticuerpos anti-cd3, anticuerpos anti-cd-123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
NI201800061A (es) Enlazadores de pd1 y/o lag3
ECSP17040521A (es) Anticuerpos heterodiméricos que se unen a CD3 y a antígenos tumorales
CL2017001361A1 (es) Anticuerpos heterodiméricos que se unen a cd3 y cd38
CO2019003945A2 (es) Proteínas de fusión heterodiméricas biespecíficas que contienen proteínas de fusión fc il-15/il-15rα y fragmentos de anticuerpo pd-1
BR112018071276A2 (pt) anticorpos anti-il-33, composições, métodos e usos dos mesmos
CR20170251A (es) Anticuerpos anti-c5 y métodos para su uso
CL2018001326A1 (es) Proteínas de unión a ctla4.
CL2019000082A1 (es) Anticuerpos específicos para la tau hiperfosforilada y sus métodos de uso.
CR20170587A (es) Terapias de combinación para enfermedades malignas hematológicas con anticuerpos anti-cd38 e inhibidores de survivina
CU24533B1 (es) Anticuerpos o fragmentos de los mismos que se unen a linfopoyetina estromal tímica (tslp) y composiciones farmacéuticas de los mismos
BR112016000666A2 (pt) Constructos de ligação de antígeno cd3 e cd19 biespecíficos
CL2015002756A1 (es) Moléculas fc biespecíficas
CU24568B1 (es) Anticuerpo inhibidor de masp-3
BR112016022841A2 (pt) cadeia j modificada
EA201591465A1 (ru) Специфичные участки для модификации антител для получения иммуноконъюгатов
ECSP14020644A (es) Anticuerpos dirigidos contra metaloproteinasas de matriz 9
CL2015001895A1 (es) Anticuerpos que se unen al tl1a y sus usos
NZ631098A (en) Anti-hepcidin antibodies and uses thereof
CL2019002894A1 (es) Anticuerpo monoclonal para pd-l1.
ECSP19018327A (es) Anticuerpo que se une específicamente a pd-1 y fragmento funcional del mismo